3 June 2022 in Translational Psychiatry
Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system. However, the interaction between bumetanide and the immune system remains unclear. Seventy-nine children with ASD were analysed from a longitudinal sample for a 3-month treatment of bumetanide. The covariation between symptom improvements and cytokine changes was calculated and validated by sparse canonical correlation analysis. Response patterns to bumetanide were revealed by clustering analysis. Five classifiers were used to test whether including the baseline information of cytokines could improve the prediction of the response patterns using an independent test sample. An immuno-behavioural covariation was identified between symptom improvements in the Childhood Autism Rating Scale (CARS) and the cytokine changes among interferon (IFN)-γ, monokine induced by gamma interferon and IFN-α2. Using this covariation, three groups with distinct response patterns to bumetanide were detected, including the best (21.5%, n = 17; Hedge’s g of improvement in CARS = 2.16), the least (22.8%, n = 18; g = 1.02) and the medium (55.7%, n = 44; g = 1.42) responding groups. Including the cytokine levels significantly improved the prediction of the best responding group before treatment (the best area under the curve, AUC = 0.832) compared with the model without the cytokine levels (95% confidence interval of the improvement in AUC was [0.287, 0.319]). Cytokine measurements can help in identifying possible responders to bumetanide in ASD children, suggesting that immune responses may interact with the mechanism of action of bumetanide to enhance the GABA function in ASD.
1 February 2025 in Molecular Psychiatry
10 February 2026 in Nature Mental Health
20 April 2026 in SSRN Electronic Journal
Background: Prenatal folic acid supplementation prevents neural tube defects, but its associations with broader neurodevelopmental outcomes are inconsistent. Folate receptor autoantibodies (FRAA) might impair folate transport to the fetus, but prospective evidence in general obstetric populations is limited.Methods: In this prospective cohort study, we analysed 3,006 mother–child pairs from the Shanghai Birth Cohort. Maternal early-pregnancy red blood cell (RBC) 5-methyltetrahydrofolate (5-MTHF) was quantified by LC-MS/MS, and maternal FRAA concentrations were measured by ELISA. Offspring neurodevelopment was assessed longitudinally at birth and ages 2, 4, and 7 years using standardised cognitive and behavioural measures. Task-related brain activation was assessed by functional near-infrared spectroscopy at ages 4 and 8 years. We examined associations of maternal RBC 5-MTHF with offspring outcomes and whether these associations were modified by FRAA and maternal milk intake.Findings: Higher maternal RBC 5-MTHF was associated with better offspring cognitive outcomes, particularly executive function, including the BRIEF Metacognition Index at age 7 years. Higher maternal folate was also associated with a steeper developmental increase in task-related activation in the left middle frontal gyrus from ages 4 to 8 years. In exploratory threshold analyses, these associations were attenuated among mothers with FRAA concentrations at or above the 70th percentile (163·87 ng/mL), including Bayley cognitive scores and language scores. This attenuation was evident in mothers with high milk intake, but not in those with low milk intake.Interpretation: Maternal FRAA might modify the neurodevelopmental associations of prenatal folate status. In this cohort, higher FRAA concentrations marked a subgroup in whom the associations between higher maternal folate and favourable offspring neurodevelopment were attenuated, particularly among mothers with higher milk intake. These findings support further evaluation of combined folate and FRAA assessment for risk stratification in pregnancy and warrant validation in independent cohorts and intervention studies.
21 May 2026 in Research Square
Prenatal folic acid supplementation prevents neural tube defects, yet its broader neurodevelopmental benefits remain inconsistent. Maternal folate receptor autoantibodies (FRAA) have been hypothesized to impair functional folate delivery to the fetal brain; however, large-scale prospective evidence in population-based pregnancy cohorts is limited. In a study of 3,006 mother-child pairs from the Shanghai Birth Cohort, we quantified maternal early-pregnancy red blood cell (RBC) 5-methyltetrahydrofolate (5-MTHF) via LC-MS/MS and measured FRAA levels via ELISA. Offspring neurodevelopment was assessed at birth and at ages 2, 4, and 7 using Bayley, WISC, BRIEF. Task-related brain activation was measured using functional near-infrared spectroscopy (fNIRS) at ages 4 and 8. Higher maternal RBC 5-MTHF was significantly associated with superior cognitive performance, particularly executive function ( β = 0.064, p = 0.024), and fNIRS data revealed a steeper developmental increase in activation within the left middle frontal gyrus ( β = 0.160, p = 0.014). Crucially, these neurodevelopmental benefits were significantly attenuated in mothers with FRAA levels at or above the 70th percentile (163.87 ng/mL; p = 0.020). This attenuation was specifically amplified by high maternal milk intake ( β = -0.007, p = 0.004), without attenuation in low milk consumers. Maternal FRAA status appears to be a critical determinant of the neurodevelopmental benefits of prenatal folate. Approximately 30% of mothers had FRAA levels at or above this susceptibility threshold (70th percentile), in whom the positive associations between maternal folate and offspring neurodevelopment were significantly attenuated. Incorporating FRAA alongside folate assessment may inform more individualized prenatal nutrition strategies for optimizing offspring neurodevelopment.